Impax Laboratories, Inc. (NASDAQ:IPXL) announced that it is commencing shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax’s generics division. RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Impax Laboratories Inc (NASDAQ:IPXL) shares after opening at $23.91 moved to $25.76 on last trade day and at the end of the day closed at $24.31. Company price to sales ratio in past twelve months was calculated as 3.31 and price to cash ratio as 4.10. Impax Laboratories Inc (NASDAQ:IPXL) showed a negative weekly performance of -1.86%.
TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company (“TherapeuticsMD” or the “Company”), announced today positive outcomes of a rabbit irritation study for TX 004-HR (formerly referred to as TX 12-004-HR), a rapidly acting estrogen vaginal preparation capsule (VagiCap). TherapeuticsMD Inc (NYSEMKT:TXMD) shares fell -1.05% in last trading session and ended the day on $4.69. TXMD return on equity ratio is recorded as -71.50% and its return on assets is -64.10%. TherapeuticsMD Inc (NYSEMKT:TXMD)yearly performance is 134.50%.
NanoViricides, Inc. (NYSEMKT:NNVC) has won the prestigious “IAIR Award” as the “Best North American Company for Leadership in the Nanomedicine Sector.” NanoViricides Inc (NYSEMKT:NNVC) shares moved up 7.12% in last trading session and was closed at $3.31 while trading in range of $3.09 – $3.39 – NanoViricides Inc (NYSEMKT:NNVC) year to date (YTD) performance is -31.04%.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented 13th Annual Needham Healthcare Conference, Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) weekly performance is -5.22%. On last trading day company shares ended up $2.36. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) distance from 50-day simple moving average (SMA50) is -19.28%. Analysts mean target price for the company is $7.50.
Leave a Reply